Geert R Kersten bought $360K of CEL-SCI (CVM)
Executed May 14, disclosed May 18, 4 days later.
Over the 21 trading sessions from the disclosed entry session (May 18), the stock returned -32.2% (delay-adjusted); from the execution session (May 14), -15.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Geert R Kersten (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales), most often in CEL-SCI Corporation (CVM). Across 3 priced purchase filings, the average 21-session return was -8.8% from execution and -26.3% from disclosure (delay-adjusted; derived). The largest single filing was $360K of CVM (300,000 sh × $1.20, as filed), executed May 14.
Healthcare · CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→100,000 sh × $1.38
Exec Aug 25
Filed Aug 26 · 8:32 AM ET CVMPURCHASE CEL-SCI Corporation $119K
100,000 sh × $1.19
Exec May 13
Filed May 14 · 8:56 AM ET CVMPURCHASE CEL-SCI Corporation $200K
38,023 sh × $5.26
Exec Jan 22
Filed Jan 26 · 8:23 AM ET CVMPURCHASE CEL-SCI Corporation $200K
29,197 sh × $6.85
Exec Jul 25 2025
Filed Jul 28 2025 · 9:36 AM ET